Generic Drug Approvals Still Winning The Pandemic At US FDA
Executive Summary
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
You may also be interested in...
FY 2019 Drug Development Drives FY 2021 User Fees Lower
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.
Teva’s Rx For GDUFA III: Treat Complex Generics More Like NDAs
New drug review elements that could benefit complex generics include a two-month filing review period before the user fee clock is triggered, more interaction between the agency and a sponsor during the review, and an opportunity for a company to have in-depth discussions with the FDA after receipt of a complete response letter, Teva’s Scott Tomsky says at kick-off meeting for next iteration of the generic drug user fee agreement.
Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: